Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Exenatide and Metformin express their anti-inflammatory effects on human monocytes/macrophages by the Attenuation of MAPKs and NFB signaling
Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies
The nucleus, along with its chromatin, undergoes expansion, ultimately leading to cell lysis driven by GSDMD-induced pore formation in the cell membrane
Injection site selection also influences needle choice
MBC News (in Korean)
)
)
)